Total Payments
$43,023
2024 Payments
$3,934
Companies
8
Transactions
48
Medicare Patients
620
Medicare Billing
$168,104
Payment Breakdown by Category
Consulting$40,421 (94.0%)
Travel$1,318 (3.1%)
Food & Beverage$1,284 (3.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $40,421 | 17 | 94.0% |
| Travel and Lodging | $1,318 | 14 | 3.1% |
| Food and Beverage | $1,284 | 17 | 3.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $22,747 | 20 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $9,099 | 9 | $0 (2023) |
| Pharmacyclics LLC, An AbbVie Company | $4,438 | 10 | $0 (2020) |
| Celgene Corporation | $2,797 | 3 | $0 (2019) |
| Genentech USA, Inc. | $2,268 | 3 | $0 (2018) |
| Adaptive Biotechnologies Corporation | $1,500 | 1 | $0 (2020) |
| BeiGene USA, Inc. | $117.75 | 1 | $0 (2024) |
| F. Hoffmann-La Roche AG | $56.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,934 | 9 | ABBVIE INC. ($3,816) |
| 2023 | $3,344 | 6 | AstraZeneca Pharmaceuticals LP ($3,344) |
| 2022 | $9,450 | 2 | ABBVIE INC. ($9,450) |
| 2021 | $5,363 | 2 | AbbVie Inc. ($5,363) |
| 2020 | $4,082 | 4 | Pharmacyclics LLC, An AbbVie Company ($1,757) |
| 2019 | $12,192 | 18 | AstraZeneca Pharmaceuticals LP ($3,450) |
| 2018 | $4,603 | 6 | AstraZeneca Pharmaceuticals LP ($2,305) |
| 2017 | $56.00 | 1 | F. Hoffmann-La Roche AG ($56.00) |
All Payment Transactions
48 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $362.50 | General |
| 12/23/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $362.50 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,900.00 | General |
| 07/29/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $40.00 | General |
| 07/29/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $26.13 | General |
| 06/29/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: ONCOLOGY | ||||||
| 06/29/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $40.00 | General |
| Category: ONCOLOGY | ||||||
| 06/29/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 01/30/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $117.75 | General |
| Category: Oncology | ||||||
| 12/17/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Oncology | ||||||
| 12/08/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | In-kind items and services | $334.45 | General |
| Category: Oncology | ||||||
| 12/08/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 12/08/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | In-kind items and services | $60.54 | General |
| Category: Oncology | ||||||
| 12/08/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $48.58 | General |
| 12/08/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $25.62 | General |
| 11/11/2022 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2022 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $6,750.00 | General |
| Category: ONCOLOGY | ||||||
| 01/07/2021 | AbbVie Inc. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| Category: ONCOLOGY | ||||||
| 01/06/2021 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $4,812.50 | General |
| 12/16/2020 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | ||||||
| 10/26/2020 | AbbVie Inc. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| Category: ONCOLOGY | ||||||
| 03/12/2020 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Oncology | ||||||
| 03/12/2020 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Travel and Lodging | In-kind items and services | $256.50 | General |
| Category: Oncology | ||||||
| 12/05/2019 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $116.35 | General |
| Category: Oncology | ||||||
| 08/04/2019 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $3,450.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 183 | 594 | $256,616 | $55,380 |
| 2022 | 7 | 182 | 660 | $273,285 | $57,623 |
| 2021 | 4 | 116 | 286 | $99,506 | $23,274 |
| 2020 | 5 | 139 | 402 | $148,821 | $31,827 |
Total Patients
620
Total Services
1,942
Medicare Billing
$168,104
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 40 | 259 | $108,230 | $25,752 | 23.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 32 | 89 | $52,954 | $10,145 | 19.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 44 | 98 | $37,148 | $7,714 | 20.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 12 | 68 | $22,714 | $5,152 | 22.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 24 | $21,154 | $3,477 | 16.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 16 | 38 | $9,218 | $1,929 | 20.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 16 | 18 | $5,198 | $1,211 | 23.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 33 | 315 | $127,438 | $26,891 | 21.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 40 | 104 | $61,233 | $12,345 | 20.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 25 | 98 | $31,338 | $7,362 | 23.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 19 | 23 | $18,327 | $3,829 | 20.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 30 | 49 | $17,760 | $3,650 | 20.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 19 | 55 | $12,694 | $2,588 | 20.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 16 | 16 | $4,495 | $959.08 | 21.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 33 | 145 | $44,619 | $11,546 | 25.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 31 | 45 | $25,369 | $5,747 | 22.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 25 | 64 | $14,376 | $3,729 | 25.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 27 | 32 | $15,142 | $2,253 | 14.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 19 | 139 | $52,006 | $12,677 | 24.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 46 | 129 | $38,643 | $8,882 | 23.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 35 | 69 | $22,445 | $4,384 | 19.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 28 | 52 | $25,822 | $3,573 | 13.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 13 | $9,905 | $2,312 | 23.3% |
About Michael Thirman
Michael Thirman is a Hematology & Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/16/2007. The National Provider Identifier (NPI) number assigned to this provider is 1356522460.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Michael Thirman has received a total of $43,023 in payments from pharmaceutical and medical device companies, with $3,934 received in 2024. These payments were reported across 48 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($40,421).
As a Medicare-enrolled provider, Thirman has provided services to 620 Medicare beneficiaries, totaling 1,942 services with total Medicare billing of $168,104. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Chicago, IL
- Active Since 11/16/2007
- Last Updated 10/24/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1356522460
Products in Payments
- VENCLEXTA (Drug) $11,313
- CALQUENCE (Drug) $9,025
- Imbruvica (Drug) $4,438
- Venclexta (Drug) $3,264
- Fedratinib (Drug) $2,797
- Rituxan (Biological) $2,268
- clonoSEQ (Device) $1,500
- BRUKINSA (Drug) $117.75
- VENCLEXTA (Biological) $56.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chicago
Michael Bishop
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Young Kwang Chae, Md, Mph, Mba, MD, MPH, MBA
Hematology & Oncology — Payments: $682,642
Hematology & Oncology $682,642
Irfan Mirza, Md, MD
Hematology & Oncology — Payments: $644,273
Hematology & Oncology $644,273
Everett Vokes
Hematology & Oncology — Payments: $449,910
Hematology & Oncology $449,910
Peter Riedell
Hematology & Oncology — Payments: $374,919
Hematology & Oncology $374,919
Rita Nanda
Hematology & Oncology — Payments: $374,678
Hematology & Oncology $374,678